Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Paper-Based Test Monitors Liver Damage

By LabMedica International staff writers
Posted on 11 Oct 2012
A postage stamp-sized, paper-based device could provide a simple and reliable way to monitor for liver damage.

The paper-based microfluidic device is inexpensive and can be employed at the point of contact to test aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels concurrently, giving doctors near real time feedback and thus allowing them to make treatment plans, if necessary, on the spot. More...


Scientists at the Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) constructed the device using layers of patterned paper and a plasma separation membrane. A hole in the lamination allows for a finger stick or pipetted drop of whole blood or serum to be applied to the plasma separation membrane. The blood then wicks into the layers of paper, and through the microfluidic channels travels to separate zones for testing AST and ALT.

Jason Rolland, PhD, Senior Director of Research at Diagnostics for All (DFA; Cambridge, MA, USA) said, “A drop of blood is applied to the device and the activity of the enzymes present in the blood sample leads to changes in levels of specific dyes present in the paper zones. This gives rise to color changes that can be compared against a visual read guide and correspond to a concentration range for each of the enzymes." The test takes about 15 minutes to perform. The color changes, for example, from shades of blue to shades of pink, when increasing levels of AST are detected in the blood. In rigorous clinical tests using 223 whole blood and serum specimens from the paper-based test performed at greater than 90% accuracy compared against the gold standard automated platform test.


Additionally, the device could be used as a "triage test" in developed or developing nations to quickly and inexpensively rule out the need for automated laboratory testing. For example, if blood tested with the device shows that the liver enzymes fall below a certain threshold, more expensive testing could be avoided, saving healthcare costs and clinical resources. Nira Pollock, MD, PhD, the co-lead author said, “The next stage for the device is to test it in the field. We are working for a preliminary field study of the paper-based test in Ho Chi Minh City, Vietnam.” The study was published on September 19, 2012, in the journal Science Translational Medicine.

Related Links:
Beth Israel Deaconess Medical Center
Diagnostics For All


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology System
Medonic M16C
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.